Opportunity
CanadaBuys #20180338
INSPQ seeks human whole blood and serum for laboratory control materials
Posted
October 30, 2026
Respond By
November 14, 2026
Identifier
20180338
NAICS
621991, 424210, 325414
The Institut national de santé publique du Québec (INSPQ) plans to obtain human blood and serum for laboratory testing and interlaboratory control materials through its Centre de toxicologie du Québec (CTQ). - Government buyer: Institut national de santé publique du Québec (INSPQ), through the Centre de toxicologie du Québec (CTQ). - Proposed supplier/OEM: BioIVT is the named source for the requested human biological materials. - Products requested: - EDTA-anticoagulated human whole blood, supplied in individual 1-litre containers. - Human serum, supplied in individual 1-litre containers. - Orders are to be placed as needed; each order may be 1 to 10 litres per matrix. No total quantity or part numbers are specified. - Notable requirements: Products must have documented collection, processing, storage, and distribution procedures; traceability by lot from collection through delivery; a controlled cold chain; and required viral testing. INSPQ may conduct preliminary analytical verification of delivered lots. - Equivalent products: Other companies may submit evidence that their products meet the technical requirements and are compatible with CTQ methods. INSPQ cites a prior open tender that received no bids as the reason for the proposed sole-source approach. - Period of performance: Estimated duration is five months.
Description
INSPQ intends to enter into a sole-source supply contract with BioIVT for human biological matrices used by the Centre de toxicologie du Québec (CTQ). The required products are EDTA-anticoagulated human whole blood and human serum, supplied in individual 1-litre containers through a standing order according to the laboratory’s needs. Orders require a minimum of 1 litre per matrix and may be up to 10 litres per matrix; products must have documented handling procedures, lot traceability, controlled cold chain, and required viral testing. Companies proposing equivalent products may submit a documented expression of interest by November 13, 2026, at 15:00 Québec time.